Case Study: Leveraging the Full Immunity Cycle: ICE® to Engage the Innate & Adaptive Immune System for Effective Anti-Tumoural Responses
Time: 9:00 am
day: Conference Day Two
Details:
- Sharing data of the multi-layered immune response of Affimed’s ICE® as mono- and combination therapy
- Outlining the development of an AB-101 NK cell product combination with AFM13 for CD30+ malignancies, such as HL and CD30-positive PTCL patients
- Highlighting early data from the combination of AFM24 with the checkpoint inhibitor atezolizumab in the treatment EGFR+ solid tumours
- Providing an update of the clinical progress of the AFM28 monotherapy study in patients with CD123+ AML
